Drug Engineered at UT Austin to Treat Anthrax Gains FDA Approval

April 4, 2016 • by Marc Airhart

The anthrax antitoxin obiltoxaximab received approval March 21 from the U.S. Food and Drug Administration (FDA).

White bacterial coloines on a plate of red culture medium

Colonies of the bacterium Bacillus anthracis, which causes anthrax, at 10x magnification. Photo credit: Todd Parker/CDC.


Share


A man smiles, in front of a chalk board with formulas written on it.

UT News

5 Questions for Dima Kozakov

Illustration shows how atom-thin materials enable control of individual photons of light

Texas Quantum Institute

Quantum Leap for STEM Graduate Training at UT